Senate Bill Aims At Streamlining Combination Product Regulation
This article was originally published in The Tan Sheet
Executive Summary
A Senate bill would streamline device/drug combination registrations by letting FDA rely on prior PMAs and approved drug findings to help support new product approvals, among other reforms. It was introduced by Sen. Johnny Isakson, R-Ga., and co-sponsored by Sens. Robert Casey, D-Pa., and Pat Roberts, R-Kansas.
You may also be interested in...
21st Century Cures: Select Device Provisions
A run-down of key provisions impacting the medical device and diagnostics industry in the 21st Century Cures legislation, which passed the House by a 344-77 vote July 10.
Combo Product Reforms Are A Priority For Next User Fee Round, FDA Officials Say
Top FDA officials, including CDRH Director Jeffrey Shuren and FDA Deputy Commissioner Robert Califf, are sending strong signals that the designation and review processes for combination products are due for a significant reassessment. That should be a priority topic of upcoming user fee negotiations with industry, they say.
Ball In Judge’s Court In Combination Product Classification Suit
All the planned briefs have been filed in a case, Prevor v. United States Food and Drug Administration, that could have important implications for how FDA designates a product for either device or drug primary review.